Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials

Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies e...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunology research 2017-01, Vol.2017 (2017), p.1-6
Main Authors: Giraldo, Paulo César, da Costa Lima, Paulo Henrique, da Silva, Janine Medeiros, Cobucci, Ricardo Ney Oliveira, Costa, Ana Paula Ferreira, Gonçalves, Ana Katherine
Format: Article
Language:English
Subjects:
Adolescent
Adult
Child
Clinical trials
Data search
Developed countries
Erythema
Erythema - etiology
Fatigue
Female
Headache
Headache - etiology
Human papillomavirus
Humans
Immunization
Immunology
Meta-analysis
Pain
Pain - etiology
Papillomaviridae - immunology
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - adverse effects
Papillomavirus Vaccines - immunology
Randomized Controlled Trials as Topic
Review
Side effects
Studies
Uterine Cervical Neoplasms - prevention & control
Vaccination
Vaccines
Viruses
Womens health
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies evaluating its safety are rare. Thus, we performed a meta-analysis of three clinical trials assessing adverse effects on women randomly vaccinated with HPV9 or tetravalent vaccine (HPV4), with the objective of analyzing whether the HPV9 is as safe as HPV4. An electronic data search was performed through the PubMed, Embase, Scopus, Web of Science, and SciELO databases. The studies selected 27,465 women who received one of the two vaccines. Pain (OR 1.72; 95% CI 1.62–1.82) and erythema (OR 1.29; 95% CI 1.21–1.36) occurred significantly more in the HPV9 group. However, there was no significant difference between the groups for the following adverse effects: headache (OR 1.07; 95% CI 0.99–1.15), dizziness (OR 1.09; 95% CI 0.93–1.27), and fatigue (OR 1.09; 95% CI 0.91–1.30), and the occurrence of serious events related to vaccination was similarly rare among those vaccinated. Therefore, our findings demonstrate that HPV9 in female patients is as safe as the tetravalent vaccine.
ISSN:2314-8861
2314-7156
DOI:10.1155/2017/3736201